THE FULL BREAKDOWN
CBN and CBD are both non-psychoactive cannabinoids found in cannabis, but their origins, abundance, and use cases differ substantially.
CBN (cannabinol) is a breakdown product of THC oxidation — meaning it’s essentially "old THC". Fresh cannabis flower contains less than 0.5% CBN. As cannabis ages with air exposure, the Δ9 THC slowly oxidizes into CBN, and the CBN concentration rises. This is why "old weed" has a reputation for being sedating — the THC has converted to CBN, which carries a strong anecdotal sleep association.
CBD (cannabidiol) is naturally produced in cannabis at much higher concentrations. CBD-rich strains can test 8–20% CBD with under 1% THC. CBD is the most-researched non-psychoactive cannabinoid, with FDA-approved use (Epidiolex for refractory pediatric epilepsy) and substantial evidence for anxiety, sleep onset, and inflammation modulation.
For sleep specifically, the picture is interesting. CBN has the cultural reputation but limited research evidence — a 2023 clinical trial showed modest CBN sleep benefits but smaller than expected. CBD has stronger research support for sleep, particularly for stress-related insomnia where its anxiolytic effects translate to easier sleep onset. Many sleep-focused products combine CBD + CBN + low-dose Δ9 THC + melatonin for stack effects.
For anxiety, CBD is the established choice. Multiple clinical trials show CBD reduces anxiety symptoms at 300–600mg doses. CBN is essentially untested for anxiety.
For consumers prioritizing sleep with cannabinoid support, the practical answer is "both": a CBD-CBN stack at evening dose. For consumers prioritizing daytime anxiety relief, CBD alone. Both are non-psychoactive, both are federally legal under the 2018 Farm Bill, both are available in stable retail products.
